Poor prognosis of young male patients with stage III colorectal cancer: A multicenter retrospective study

被引:6
|
作者
Okamoto, Kazuaki [1 ]
Sasaki, Kazuhito [1 ]
Nozawa, Hiroaki [1 ]
Murono, Koji [1 ]
Emoto, Shigenobu [1 ]
Yamauchi, Shinichi [2 ]
Sugihara, Kenichi [2 ]
Ishihara, Soichiro [1 ]
机构
[1] Univ Tokyo, Dept Surg Oncol, 7-3-1 Hongo,Bunkyo ku, Tokyo 1138655, Japan
[2] Tokyo Med & Dent Univ, Dept Gastrointestinal Surg, Tokyo, Japan
关键词
colorectal cancer; prognosis; sex; tumor sidedness; young; HORMONE REPLACEMENT THERAPY; IMPROVED SURVIVAL; COLON-CANCER; EARLY-ONSET; AGE; WOMEN; IMPACT; RISK;
D O I
10.1002/jso.27557
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Objectives: The number of young patients with colorectal cancer (CRC) is increasing. However, sex-dependent differences in the prognosis of young CRC remain unknown.Methods: We investigated patients aged <70 years with stage III CRC treated between January 2000 and December 2010 in 24 Japanese referral hospitals. Patients were divided into subgroups by age of 50 years (early-onset and late-onset groups) and sex, and clinical characteristics and survival outcomes were compared. Risk factors associated with poor survival outcomes were also analyzed.Results: Among 4758 consecutive patients, 771 (16%) were <50 years. Regardless of sex, there were more patients with rectal cancer and treated with adjuvant chemotherapy in the early-onset group. Among males, tumors in the early-onset group were poorly differentiated (p < 0.001), and patients were diagnosed at an advanced N stage (p = 0.010). Among females, there were more patients with left-sided cancer in the early-onset group (p < 0.001). Relapse-free survival (RFS) and overall survival (OS) were worse in the early-onset group than in the late-onset group (5-year RFS rates: 58% and 63%, p = 0.024; 5-year OS rates: 76% and 81%, p = 0.041, respectively), while there were no age-dependent differences in the survival outcomes of female CRC patients. A multivariate analysis identified age <50 years as one of the independent risk factors associated with poor RFS in male stage III CRC patients (p = 0.032)Conclusions: Young male patients with stage III CRC showed poorer survival outcomes than their older counterparts. Therefore, age- and sex-related differences in the incidence of CRC recurrence need to be considered.
引用
收藏
页码:785 / 792
页数:8
相关论文
共 50 条
  • [21] Down-regulated MYH11 Expression Correlates with Poor Prognosis in Stage II and III Colorectal Cancer
    Wang, Ren-Jie
    Wu, Peng
    Cai, Guo-Xiang
    Wang, Zhi-Min
    Xu, Ye
    Peng, Jun-Jie
    Sheng, Wei-Qi
    Lu, Hong-Fen
    Cai, San-Jun
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (17) : 7223 - 7228
  • [22] Gastric cancer in young patients: a separate entity with aggressive features and poor prognosis
    Cheng, Lyujia
    Chen, Songyao
    Wu, Wenhui
    Kuo, Zi Chong
    Wei, Zhewei
    Meng, Sijun
    Chen, Chuangqi
    Zhang, Changhua
    He, Yulong
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (11) : 2937 - 2947
  • [23] E-selectin gene S128R polymorphism is associated with poor prognosis in patients with stage II or III colorectal cancer
    Hebbar, Mohamed
    Adenis, Antoine
    Revillion, Francoise
    Duhamel, Alain
    Romano, Olivier
    Truant, Stephanie
    Libersa, Christian
    Giraud, Claire
    Triboulet, Jean-Pierre
    Pruvot, Francois-Rene
    Peyrat, Jean-Philippe
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (10) : 1871 - 1876
  • [24] Hypomethylation of LINE-1 in primary tumor has poor prognosis in young breast cancer patients: a retrospective cohort study
    van Hoesel, Anneke Q.
    van de Velde, Cornelis J. H.
    Kuppen, Peter J. K.
    Liefers, Gerrit Jan
    Putter, Hein
    Sato, Yusuke
    Elashoff, David A.
    Turner, Roderick R.
    Shamonki, Jaime M.
    de Kruijf, Esther M.
    van Nes, Johanna G. H.
    Giuliano, Armando E.
    Hoon, Dave S. B.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (03) : 1103 - 1114
  • [25] Effectiveness of adjuvant chemotherapy in patients with Stage II colorectal cancer: A multicenter retrospective study
    Jalaeikhoo, Hasan
    Zokaasadi, Mohammad
    Khajeh-Mehrizi, Ahmad
    Rajaeinejad, Mohsen
    Mousavi, Seied Asadollah
    Vaezi, Mohammad
    Fumani, Hosein Kmranzadeh
    Keyhani, Manoutchehr
    Alimoghaddam, Kamran
    Ghavamzadeh, Ardeshir
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2019, 24
  • [26] Metabolic Syndrome-Related Hyperuricemia is Associated with a Poorer Prognosis in Patients with Colorectal Cancer: A Multicenter Retrospective Study
    Feng, Qian
    Tang, Liang-Jie
    Luo, Ding-Hai
    Wang, Ying
    Wu, Nan
    Chen, Hao
    Chen, Meng-Xia
    Jiang, Lei
    Jin, Rong
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 8809 - 8819
  • [27] TMPRSS4 overexpression promotes the metastasis of colorectal cancer and predicts poor prognosis of stage III-IV colorectal cancer
    Zhao, Xue-Feng
    Yang, Yu-Shen
    Gao, Da-Zhi
    Park, Young Kyu
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2021, 36 (03) : 23 - 32
  • [28] Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients
    Fu, Tao
    Liu, Yanliang
    Li, Kai
    Wan, Weiwei
    Pappou, Emmanouil P.
    Iacobuzio-Donahue, Christine A.
    Kerner, Zachary
    Baylin, Stephen B.
    Wolfgang, Christopher L.
    Ahuja, Nita
    ONCOTARGET, 2016, 7 (52) : 86480 - 86489
  • [29] Preoperative iron status is a prognosis factor for stage II and III colorectal cancer
    Sawayama, Hiroshi
    Miyamoto, Yuji
    Mima, Kosuke
    Kato, Rikako
    Ogawa, Katsuhiro
    Hiyoshi, Yukiharu
    Shimokawa, Mototsugu
    Akiyama, Takahiko
    Kiyozumi, Yuki
    Iwagami, Shiro
    Iwatsuki, Masaaki
    Baba, Yoshifumi
    Yoshida, Naoya
    Baba, Hideo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (11) : 2037 - 2045
  • [30] High MEIS3 Expression Indicates a Poor Prognosis for Patients with Stage II/III Colorectal Cancer
    Ma, Jian
    Li, Haitao
    Gao, Qianqian
    Zhang, Weixing
    Zhu, Changhong
    Chen, Jian
    Ling, Yang
    Shao, Xin
    Li, Ziyan
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2023, 28 (12):